نتائج البحث - Per Odin

تنقيح النتائج
  1. 1
    Algorithms for the treatment of motor problems in Parkinson's disease

    Algorithms for the treatment of motor problems in Parkinson's disease حسب Espen Dietrichs, Per Odin

    منشور في 2017
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Subcutaneous apomorphine in late stage Parkinson's disease: a long term follow up

    Subcutaneous apomorphine in late stage Parkinson's disease: a long term follow up حسب K. Pietz, Peter Hagell, Per Odin

    منشور في 1998
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Caregiver Burden and Quality of Life in Late Stage Parkinson’s Disease

    Caregiver Burden and Quality of Life in Late Stage Parkinson’s Disease حسب Kristina Rosqvist, Anette Schrag, Per Odin

    منشور في 2022
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Immunohistochemical localization of cellCAM 105 in rat tissues: appearance in epithelia, platelets, and granulocytes.

    Immunohistochemical localization of cellCAM 105 in rat tissues: appearance in epithelia, platelets, and granulocytes. حسب Per Odin, Maria Asplund, Chia‐Jung Busch, Björn Öbrink

    منشور في 1988
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    Fall-related activity avoidance in relation to a history of falls or near falls, fear of falling and disease severity in people with Parkinson’s disease

    Fall-related activity avoidance in relation to a history of falls or near falls, fear of falling and disease severity in people with Parkinson’s disease حسب Manzur Kader, Susanne Iwarsson, Per Odin, Maria H Nilsson

    منشور في 2016
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    Continuous Drug Delivery Aiming Continuous Dopaminergic Stimulation in Parkinson’s Disease

    Continuous Drug Delivery Aiming Continuous Dopaminergic Stimulation in Parkinson’s Disease حسب Daniel J. van Wamelen, Sotirios Grigoriou, К. Ray Chaudhuri, Per Odin

    منشور في 2018
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    Factors associated with life satisfaction in Parkinson's disease

    Factors associated with life satisfaction in Parkinson's disease حسب Kristina Rosqvist, Peter Hagell, Per Odin, Henrik Ekström, Susanne Iwarsson, Maria H Nilsson

    منشور في 2016
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  8. 8
    Validation of the PD home diary for assessment of motor fluctuations in advanced Parkinson’s disease

    Validation of the PD home diary for assessment of motor fluctuations in advanced Parkinson’s disease حسب Matthias Löhle, Alexander Bremer, Florin Gandor, Jonathan Timpka, Per Odin, Georg Ebersbach, Alexander Storch

    منشور في 2022
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  9. 9
    Pharmacokinetics of Levodopa, Carbidopa, and 3-O-Methyldopa Following 16-hour Jejunal Infusion of Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson’s Disease Patients

    Pharmacokinetics of Levodopa, Carbidopa, and 3-O-Methyldopa Following 16-hour Jejunal Infusion of Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson’s Disease Patients حسب Dag Nyholm, Per Odin, Anders Johansson, Krai Chatamra, Charles Locke, Sandeep Dutta, Ahmed A. Othman

    منشور في 2012
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  10. 10
    Impact of age at onset on symptom profiles, treatment characteristics and health-related quality of life in Parkinson’s disease

    Impact of age at onset on symptom profiles, treatment characteristics and health-related quality of life in Parkinson’s disease حسب Lars Lau Rakêt, Daniel Oudin Åström, Jenny M. Norlin, Klas Kellerborg, Pablo Martínez‐Martín, Per Odin

    منشور في 2022
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  11. 11
    Transdermal rotigotine for the perioperative management of Parkinson’s disease

    Transdermal rotigotine for the perioperative management of Parkinson’s disease حسب Ullrich Wüllner, Jan Kassubek, Per Odin, Michael Schwarz, Markus Naumann, Hermann-Josef Häck, Babak Boroojerdi, Heinz Reichmann

    منشور في 2010
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  12. 12
    Non-oral dopaminergic therapies for Parkinson’s disease: current treatments and the future

    Non-oral dopaminergic therapies for Parkinson’s disease: current treatments and the future حسب К. Ray Chaudhuri, Mubasher A. Qamar, Thadshani Rajah, Philipp Alexander Loehrer, Anna Sauerbier, Per Odin, Peter Jenner

    منشور في 2016
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  13. 13
    Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson’s disease: a multi-country Delphi-panel approach

    Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson’s disease: a multi-country Delphi-panel appr... حسب Angelo Antonini, A. Jon Stoessl, Leah Kleinman, Anne Skalicky, Thomas S. Marshall, Kavita Sail, Koray Onuk, Per Odin

    منشور في 2018
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  14. 14
    Management of Advanced Therapies in Parkinson's Disease Patients in Times of Humanitarian Crisis: The <scp>COVID</scp>‐19 Experience

    Management of Advanced Therapies in Parkinson's Disease Patients in Times of Humanitarian Crisis: The <scp>COVID</scp>‐19 Experience حسب Alfonso Fasano, Angelo Antonini, Regina Katzenschlager, Paul Krack, Per Odin, Andrew Evans, Thomas Foltynie, Jens Volkmann, Marcelo Merello

    منشور في 2020
    احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  15. 15
    The Non‐Motor Symptoms Scale in Parkinson’s disease: Validation and use

    The Non‐Motor Symptoms Scale in Parkinson’s disease: Validation and use حسب Daniel J. van Wamelen, Pablo Martínez‐Martín, Daniel Weintraub, Anette Schrag, Angelo Antonini, Cristian Falup‐Pecurariu, Per Odin, К. Ray Chaudhuri

    منشور في 2020
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  16. 16
    Peripheral neuropathy in Parkinson's disease: Levodopa exposure and implications for duodenal delivery

    Peripheral neuropathy in Parkinson's disease: Levodopa exposure and implications for duodenal delivery حسب Thomas Müller, Teus van Laar, David R. Cornblath, Per Odin, Fabian Klostermann, Francisco Grandas, Georg Ebersbach, Péter Urbán, Francesc Valldeoriola, Angelo Antonini

    منشور في 2013
    احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  17. 17
    Pen injected apomorphine against off phenomena in late Parkinson's disease: a double blind, placebo controlled study.

    Pen injected apomorphine against off phenomena in late Parkinson's disease: a double blind, placebo controlled study. حسب Lauge Østergaard, Lene Werdelin, Per Odin, Olle Lindvall, E. Dupont, Peter Brøgger Christensen, E Boisen, Niels Bjørn Jensen, SH Ingwersen, Michelle Schmiegelow

    منشور في 1995
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  18. 18
    Viewpoint and practical recommendations from a movement disorder specialist panel on objective measurement in the clinical management of Parkinson’s disease

    Viewpoint and practical recommendations from a movement disorder specialist panel on objective measurement in the clinical management of Parkinson’s disease حسب Per Odin, К. Ray Chaudhuri, Jens Volkmann, Angelo Antonini, Alexander Storch, Espen Dietrichs, Zvezdan Pirtošek, Tove Henriksen, Malcolm Horne, David Devos, Filip Bergquist

    منشور في 2018
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  19. 19
    The Long-Term Impact of Levodopa/Carbidopa Intestinal Gel on ‘Off’-time in Patients with Advanced Parkinson’s Disease: A Systematic Review

    The Long-Term Impact of Levodopa/Carbidopa Intestinal Gel on ‘Off’-time in Patients with Advanced Parkinson’s Disease: A Systematic Review حسب Angelo Antonini, Per Odin, Rajesh Pahwa, Jason Aldred, Ali Alobaidi, Yash J. Jalundhwala, Pavnit Kukreja, Lars Bergmann, Sushmitha Inguva, Yanjun Bao, К. Ray Chaudhuri

    منشور في 2021
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  20. 20
    Digital health technology for non-motor symptoms in people with Parkinson's disease: Futile or future?

    Digital health technology for non-motor symptoms in people with Parkinson's disease: Futile or future? حسب Daniel J. van Wamelen, Jirada Sringean, Dhaval Trivedi, Camille Carroll, Anette Schrag, Per Odin, Angelo Antonini, Bastiaan R. Bloem, Roongroj Bhidayasiri, К. Ray Chaudhuri

    منشور في 2021
    احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: